uniQure Announces 2017 Financial Results and Recent Company Progress

08:00 EDT 14 Mar 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
~ On Track to Begin Pivotal Study of AMT-061 in Hemophilia B in Q3 2018 ~ Submitted IND Amendment for AMT-061 Dose Confirmation Study, with Topline Data Expected by End of 2018 ~ Expects IND Submission for AMT-130 in Huntington's Disease in the...

Other Sources for this Article


More From BioPortfolio on "uniQure Announces 2017 Financial Results and Recent Company Progress"

Quick Search


Relevant Topics

Huntington's Disease
Huntington's disease is a hereditary disease caused by a defect in a single gene on Chromosome 4 that is inherited in an autosomal dominant fashion. The defect causes a part of DNA, called a CAG repeat, to occur many more times than it is supposed to...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...